ReleaseWire Connect

Debra Hoffmeyer, CEO & Founder of CITrials, recently conducted a Zoom meeting with many key leaders and stakeholders in global clinical research to discuss the impact of COVID-19 crisis on the clinical trial industry. In this global meet, Debra discussed continuing clinical trials, continuity and contingency plans, and ensuring stability and infrastructure for sites during this coronavirus pandemic. The meeting was attended by major pharmaceutical companies like Eli Lilly, Intra-Cellular Therapies, Acadia Pharmaceuticals, Otsuka Pharmaceuticals, BMS Pharma Cervelo Pharmaceuticals, FDA, EUDA, Japan FDA, Italian drug authorities, and many others.

CITrials, the name setting new benchmarks in the healthcare industry, has received approval for its multiple sites from IRB for Roche Pharmaceuticals' schizophrenia program. With this approval, CITrials will now be able to test the effectiveness of novel antipsychotic medication on people diagnosed with schizophrenia.

CITrials, an advanced medical research company, is now working with Roche Pharmaceuticals to develop a novel treatment for people suffering from schizophrenia. By collaborating with a pioneer in the healthcare industry, CITrials is committed to groundbreaking scientific and technological advances that have the potential to transform the lives of people suffering from schizophrenia.

It is more important than ever to take care of one another and be diligent and wise in our daily activities.

A leading clinical research facility, CITrials clinical work has helped Merck to get FDA approval for a new use of its insomnia drug Belsomra, treating sleep disruption in people with mild-to-moderate Alzheimer's disease. The approval for this label is based on clinical trials done in CITrials. Belsomra's activity in Alzheimer's was demonstrated in a 285-subject, four-week sleep study, published in Alzheimer's & Dementia, which found significant improvements compared to placebo in total sleep time (TST) and wake after sleep onset (WASO) measures.

CITrials has new milestones to showcase at ISCTM 16th Annual Scientific Meeting. The event is being held at The Grand Hyatt, Washington D.C. from February 19th to 21st. Since the previous annual meeting, the research center has come a long way producing exceptional results in the research of many illnesses. The center has since published its extensive and systematic research on adult verbal disfluency. With a commitment to provide effective treatment and advancing medical research, the research center assists patients in managing their healthcare.

CITrials, the advanced medical research company is participating in the 2020 European Site Solutions Summit to be held on 09-10th March 2020 in Lisbon Portugal. The summit will be organized by The Society for Clinical Research Sites (SCRS), an active partner in industry-wide dialogues and initiatives focused on enhancing the clinical research enterprise.

CITrials, the Pharmaceutical Medical Research clinical trials facility, participated in the 16th Annual Scientific Meeting that was held from 19-21 February 2020 in Grand Hyatt - Washington, DC. The event was organized by ISCTM (International Society for CNS Clinical Trials and Methodology).

Clinical trials are one of the best ways to discover newer ways of preventing, detecting and treating diseases. From mental to physical, clinical trials are conducted for thousands of diseases. Arthritis is among the few common physical diseases for which clinical trials has been conducted over the years. A clinical research organization, like CITrials conducts clinical trials to find the best possible medical treatments for Arthritis. They have a team of board-certified physician-researchers specializing in conducting Phase I-IV clinical trials for patients with Arthritis.

Arthritis is one of the most leading causes of pain and disability worldwide. There are more than 100 different types of arthritis and related diseases. However, the most common types of arthritis are osteoarthritis and rheumatoid. In the United States, arthritis affects more than 50 million adults and 300,000 children.